Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Recommendation of "Reduce" from Brokerages

Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) have been assigned an average rating of "Reduce" from the seventeen research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $200.79.

CRL has been the topic of a number of recent research reports. Bank of America dropped their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Morgan Stanley cut their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. The Goldman Sachs Group decreased their price target on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Finally, Redburn Atlantic assumed coverage on Charles River Laboratories International in a research note on Monday, October 14th. They issued a "sell" rating and a $151.00 price objective for the company.

Charles River Laboratories International Stock Performance

CRL stock traded down $3.89 during trading on Friday, hitting $159.90. The company had a trading volume of 1,709,558 shares, compared to its average volume of 968,210. The firm has a 50-day moving average price of $179.79 and a 200-day moving average price of $192.80. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm has a market cap of $8.18 billion, a PE ratio of 20.01, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. Charles River Laboratories International has a 1-year low of $157.41 and a 1-year high of $275.00.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently modified their holdings of CRL. Versant Capital Management Inc boosted its holdings in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in shares of Charles River Laboratories International in the third quarter valued at about $32,000. Pinnacle Bancorp Inc. raised its stake in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares during the period. Assetmark Inc. lifted its holdings in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after buying an additional 173 shares in the last quarter. Finally, Tortoise Investment Management LLC boosted its holdings in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).